Product NDC: | 47335-083 |
Proprietary Name: | LIPODOX 50 |
Non Proprietary Name: | Doxorubicin Hydrochloride |
Active Ingredient(s): | 2 mg/mL & nbsp; Doxorubicin Hydrochloride |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTABLE, LIPOSOMAL |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 47335-083 |
Labeler Name: | Sun Pharma Global FZE |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | |
Marketing Category: | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
Start Marketing Date: | 20120209 |
Package NDC: | 47335-083-50 |
Package Description: | 1 VIAL, SINGLE-USE in 1 PACKAGE (47335-083-50) > 25 mL in 1 VIAL, SINGLE-USE |
NDC Code | 47335-083-50 |
Proprietary Name | LIPODOX 50 |
Package Description | 1 VIAL, SINGLE-USE in 1 PACKAGE (47335-083-50) > 25 mL in 1 VIAL, SINGLE-USE |
Product NDC | 47335-083 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Doxorubicin Hydrochloride |
Dosage Form Name | INJECTABLE, LIPOSOMAL |
Route Name | INTRAVENOUS |
Start Marketing Date | 20120209 |
Marketing Category Name | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
Labeler Name | Sun Pharma Global FZE |
Substance Name | DOXORUBICIN HYDROCHLORIDE |
Strength Number | 2 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA] |